Previous Article | Next Article ![]()
Journal of Bacteriology, October 2004, p. 6508-6514, Vol. 186, No. 19
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.19.6508-6514.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Microbiology and Immunology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda,1 Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland2
Received 3 May 2004/ Accepted 7 July 2004
|
|
|---|
|
|
|---|
1,4-GalNAc-
1,4-(Glc-ß1,3-)GalNAc-
1,4-GalNAc-
1,4-GalNAc-
1,3-bacillosamine (38). There are several genes in the C. jejuni pgl locus that have been shown to be involved in distinct steps in N-linked glycosylation (38). The addition of the glycan is dependent on the activity of the PglB protein, which is predicted to function as an oligosaccharide transferase (29, 32, 38) based on its homology to an oligosaccharide transferase subunit (STT3) of Saccharomyces cerevisiae (39). Other pgl genes (pglF, pglE, and pglD) have been proposed to be involved in synthesis of bacillosamine, a sugar that appears to be specific to this N-linked glycan (32, 38). Mutation of either pglB or pglE diminished the ability of 81-176 to invade INT407 cells and colonize the intestinal tracts of mice (28), reinforcing the importance of protein glycosylation to the pathogenesis of C. jejuni. However, the precise functional contribution of N-linked glycosylation to the pathogenesis of C. jejuni remains unclear. C. jejuni strain 81-176 possesses two plasmids, one of which, pVir, is nonconjugative and affects both virulence and natural competence (2). Sequence analysis of this plasmid revealed the presence of eight genes with greatest homology to a type IV secretion system (TFSS) subsequently shown to be present in the ruminant commensal Wolinella succinogenes (1, 3). There is also significant homology to two TFSS found in Helicobacter pylori. These are the com system, which is responsible for natural transformation in H. pylori, and a more recently described TFSS of unknown function found in the H. pylori J99 plasticity zone (15, 16, 19). In contrast, the pVir TFSS shows much less homology to the well-characterized TFSS found on the cag pathogenicity island of H. pylori (7, 31). TFSS, which are present in a variety of plant and mammalian pathogens, are involved in the transfer of DNA, protein, or nucleoprotein complexes across bacterial membranes (8). The TFSS genes present on pVir have been proposed to encode proteins that form a functional secretion channel that appears to affect both intestinal epithelial cell invasion and natural competence (2, 3).
Herein we report that a putative structural component of the pVir TFSS, VirB10 (Cjp3) (3), is glycosylated by the pgl system at two asparagines residues and that lack of glycosylation at one site results in a competence defect comparable to that of the virB10 mutant. Further, we demonstrate that pgl mutants exhibit a major defect in natural competence, suggesting that N-linked glycosylation is required for full competence in C. jejuni 81-176.
|
|
|---|
transformed with the C. jejuni pgl genes present on pACYC184 (pBTLPS) has been described previously (32). E. coli strains were grown on Luria agar. E. coli DH5
was used as the host strain for cloning experiments, and DH5
containing pRK212.1 was used as the donor in conjugation experiments (10). E. coli ER2566 (New England Biolabs, Beverly, Mass.) was used as the host strain for protein expression experiments. Antibiotics were added when appropriate to the following concentrations: 100 µg of ampicillin per ml, 20 µg of chloramphenicol per ml, 25 µg of kanamycin per ml, 20 µg of streptomycin per ml, 20 µg of tetracycline per ml, and 10 µg of trimethoprim per ml. Plasmids used are listed in Table 1. |
View this table: [in a new window] |
TABLE 1. Plasmids used
|
70 promoter, was PCR amplified with HF2 DNA polymerase (Clontech, Palo Alto, Calif.) with the following primers: 5'-CGGGATCCCGAAAATTCTCCTACAAAATTTAAGAAC-3' and 5'-GCTCTAGAGCTTTTAACCTTTTAATATTAGTAATTTTTT-3'. These primers introduced BamHI and XbaI sites bracketing the promoter region of Cj1291. The PCR product was digested with BamHI and XbaI and was cloned into BamHI-XbaI digested pRY107, a kanamycin-resistant shuttle vector (37), to generate pCE107/70. The region upstream of the flaA gene containing the
28 promoter was PCR amplified from 81-176 by using HF2 DNA polymerase (Clontech) with the following primers: 5'-GCTCTAGAGCGTAAAATTGAAGATGAAAGAGAG-3' and 5'-CGGGATCCCGTTTTAAATCCTTTTAAATAATTTC-3'. These primers introduced XbaI and BamHI sites, respectively. The PCR product was digested with XbaI and BamHI (New England Biolabs) and cloned into XbaI-BamHI-digested pRY111, a chloramphenicol-resistant campylobacter shuttle plasmid (37), to generate pCE111/28.
Complementation in trans of the virB10 mutation.
PCR amplification was used to amplify virB10 (cjp3) from the pVir plasmid by using HF2 DNA polymerase (Clontech). The primers to amplify cjp3/virB10 were JCL 075 (5'-CGCGGATCCATGAAAAAATCCTTTTTAAGCC-3') and JCL 076 (5'-GGCTGCAGTTAATTATCTTGGAAATATTGG-3'), which introduced BamHI and PstI sites (5' and 3', respectively) flanking the virB10 coding sequence. The amplicon was digested with BamHI and PstI and was cloned into the BamHI and PstI sites of pCE107/70 or pCE111/28 to create pJL101 or pJL102, respectively. The pJL102 construct and mutant derivatives were mobilized from E. coli DH5
containing pRK212.1 into C. jejuni DB179 virB10::Km cells. Transconjugants were selected on MH agar containing kanamycin, chloramphenicol, and trimethoprim. Plasmid pJL101 was transformed into E. coli DH5
with or without pBTLPS (32).
Site-directed mutagenesis of virB10. Mutation of five of the six predicted N-linked glycosylation sites of VirB10 was carried out using the Quickchange site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). Mutations were confirmed by sequencing with a Big Dye Terminator sequencing kit (Applied Biosystems, Foster City, Calif.) on an ABI Prism 3100 genetic analyzer (Applied Biosystems). Oligonucleotides used are listed in Table 2. The construction of the single mutants was carried out with pJL102 as a template, and pJL102/N32A was used as the template to construct the double mutant, pJL102/N32, N97A.
|
View this table: [in a new window] |
TABLE 2. Oligonucleotides used for the site-directed mutagenesis of C. jejuni virB10
|
Generation of polyclonal antisera. Protein samples were sent for injection into New Zealand White Rabbits at Harlan Bioproducts (Indianapolis, Ind.). Following the manufacturer's immunization protocol, polyclonal antisera were obtained and used at the indicated dilutions.
Electrophoresis and immunoblotting. Campylobacter spp. and E. coli whole cells were resuspended in 1x sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) sample buffer to a final protein concentration of 10 µg/µl. Protein samples were aliquoted and resuspended in an equal volume of 2x SDS-PAGE sample buffer. Samples were boiled and loaded onto 10% acrylamide gels. Proteins were separated by SDS-PAGE (21) and were detected by staining with Coomassie brilliant blue G250 or, after transfer to nitrocellulose, Western blot analysis using the indicated rabbit antisera. The secondary antibody was goat anti-rabbit antiserum conjugated to alkaline phosphatase (Caltag, Burlingame, Calif.) used at a 1:5,000 dilution.
SBA affinity columns. Glycine extracts were prepared by resuspending a loopful of campylobacter organisms in 0.2 M glycine-HCl, pH 2.2, and placing it on ice for 10 min. Samples were centrifuged at 16,000 x g and suspended in an equal volume of 2x SDS-PAGE sample buffer. Large-scale glycine extracts were prepared with 100 ml of C. jejuni grown in biphasic culture as previously described (24). Prepared glycine extracts were incubated with 2 ml of soybean agglutinin (SBA) agarose (Vector Labs, Burlingame, Calif.) at 4°C. Following the collection of flowthrough fractions, the column was washed in 20 ml of column buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.1 mM CaCl2, and 0.01 mM MnCl2) and wash fractions were collected. Proteins were eluted from the column by washing with 3 bed volumes of column buffer containing 0.2 M galactose.
Enzymatic deglycosylation.
Neutralized glycine extracts of C. jejuni were treated with
-N-acetyl-galactosaminidase or ß-N-acetylhexosaminidase (New England Biolabs) according to the manufacturer's recommendations. After the addition of an equal volume of 2x SDS-PAGE loading buffer, samples were boiled and loaded onto a 10% acrylamide gel.
Natural transformation of C. jejuni. The biphasic natural transformation procedure was used as previously described (33). C. jejuni strains were grown overnight on plates and were resuspended in MH broth to an optical density at 600 nm of 1.0. Aliquots of 250 µl of each strain were grown for an additional 2 h at 37°C in biphasic culture tubes (13). DNA (500 ng) from a streptomycin-resistant mutant of 81-176 (13) was added to cultures, and incubation continued for 4 h at 37°C. Cultures were serially diluted and plated in duplicate to MH agar containing streptomycin. The results were expressed as the number of transformants per microgram of Strr DNA. Negative controls were treated identically without the addition of DNA.
|
|
|---|
![]() View larger version (79K): [in a new window] |
FIG. 1. Discrepancy in mass of VirB10 expressed in C. jejuni and E. coli. Immunoblot of recombinant VirB10 isolated from E. coli and glycine extracts from C. jejuni DB179 and isogenic virB10 mutant. Protein samples were separated on a 10% acrylamide gel. Blots were incubated with an anti-VirB10 antiserum at 1:50,000 dilution. Lane 1, DB179; lane 2, DB179 (pVir/virB10::Km); lane 3, recombinant VirB10.
|
![]() View larger version (52K): [in a new window] |
FIG. 2. VirB10 possesses affinity for SBA. Neutralized glycine extracts of DB179 were subjected to column chromatography with a SBA-agarose column. Extract, flowthrough, wash, and elution fractions were subjected to SDS-PAGE, blotted onto membranes, and incubated with either anti-VirB8 (A), anti-VirB9 (B), or anti-VirB10 antisera (C) at a 1:50,000 dilution. Lane 1, glycine extract from DB179; lane 2, column flowthrough fraction; lane 3, wash fraction; lanes 4 to 8, elution fractions.
|
-N-acetylgalactosaminidase, which cleaves the internal
1,3-linked N-acetylgalactosamine residue from the rest of the glycan, VirB10 mobility decreased on SDS-PAGE gels (Fig. 3, lane 2). Treatment with ß-N-acetylhexosaminidase, which cleaves terminal ß1-, ß2-, ß3-, ß4-, and ß6-linked GalNAc and N-acetylglucosamine residues, resulted in no discernible difference in mass (Fig. 3, lane 3). These data indicate that the glycan present on VirB10 contains an
1,3-linked GalNAc, consistent with the structure of the campylobacter N-linked glycan previously reported (38).
![]() View larger version (56K): [in a new window] |
FIG. 3. VirB10 is susceptible to treatment with N-acetylgalactosaminidase. Neutralized glycine extracts of C. jejuni DB179 were untreated (lane 1), treated with N-acetylgalactosaminidase (lane 2), or treated with ß-N-acetylhexosaminidase (lane 3). Samples were separated on a 10% acrylamide gel, blotted onto membranes, and incubated with anti-VirB10 antiserum at a 1:50,000 dilution.
|
in the absence of the pgl system, two bands were visible (Fig. 4, lane 3). The major band corresponded to the mass of recombinant, unglycosylated VirB10 (Fig. 4, lane 1) lacking a signal peptide (40.5 kDa). The minor band in these whole-cell extracts, of approximately 41.5 kDa, likely represents VirB10 without its leader sequence removed (see below). In DH5
containing both pBTLPS, carrying the intact pgl operon (32), and pJL101, bands of similar apparent mass were observed (Fig. 4, lane 5) as well as an additional band that corresponded to the mass of the glycosylated form of VirB10 expressed in DB179 (Fig. 4, lane 6). When a clarified whole-cell extract from DH5
(pBTLPS, pJL101) was subjected to column chromatography using the SBA-agarose column, the major band detected in the elution fractions (Fig. 4, lane 7) corresponded in mass to that of glycosylated VirB10 expressed in DB179 (lane 6); there was also a minor band that had the same apparent mass as the middle band shown in lane 5 (see below). When a lysate from DH5
containing pJL101 but not pBTLPS was passed over SBA agarose, no VirB10 could be detected in the elution fractions by immunoblot (data not shown). |
View larger version (20K): [in a new window] |
FIG. 4. Analysis of VirB10 expressed in E. coli DH5 in the presence or absence of the C. jejuni pgl system. Whole-cell extracts of E. coli were prepared and separated on a 10% acrylamide gel, blotted, and immunodetected with VirB10 antisera at 1:100,000 dilution. Lane 1, purified recombinant VirB10 from E. coli; lane 2, E. coli DH5 (pCE107/70), the vector-only control; lane 3, E. coli DH5 (pJL101), expressing virB10 in the absence of the pgl system; lane 4, E. coli DH5 (pBTLPS) containing the pgl genes cloned into pACYC184 (32); lane 5, E. coli DH5 (pBTLPS, pJL101), expressing virB10 in the presence of the pgl system; lane 6, control of a glycine extract from C. jejuni DB179; lane 7, elution fraction from SBA column of lysates from E. coli DH5 (pBTLPS, pJL101).
|
![]() View larger version (22K): [in a new window] |
FIG. 5. VirB10 is absent in the periplasm of mutants defective in the general protein glycosylation pathway of C. jejuni. Glycine extracts of C. jejuni DB179 and mutants were separated on a 10% acrylamide gel and were blotted, and membranes were probed with either VirB8 (A), VirB9 (B), or VirB10 (C) antisera at a 1:50,000 dilution. Lanes 1, C. jejuni DB179; lanes 2, 81-176 virB8::Cm (A), 81-176 virB9::Cm (B), or DB179 virB10::Km (C); lanes 3, 81-176 pglE::Km; lane 4 of panel C, 81-176 pglE::Km (pCS101) (29).
|
28 promoter, to generate asparagine-to-alanine substitutions in five of these six possible glycosylation sites. Figure 6 shows a Western blot of glycine-extracted proteins of the DB179 virB10::Km mutant complemented in trans with selected mutated derivatives of pJL102. Alanine substitution of N32 of VirB10 (Fig. 6, lane 4) resulted in a decrease in mass such that the VirB10 band migrated at a position similar to that of the minor 41.5-kDa band seen in glycine extracts of DB179 (Fig. 6, lane 1). Mutation of N97 of VirB10 resulted in the presence of two equally intense bands (lane 5). The first band corresponded to the minor 41.5-kDa form of VirB10 detected in glycine extracts of DB179 (lane 1) and to that seen in N32A mutant (lane 4). The lower band migrated in parallel to the recombinant unglycosylated form of the protein expressed in E. coli (Fig. 6, lane 7). When both N32 and N97 were mutated in the same plasmid (lane 6), only one band was detected that was of the same apparent mass as the recombinant, nonglycosylated form of VirB10 (lane 7). Mutation of three other putative N-linked glycosylation sites of VirB10 (N42, N126, and N156) resulted in no discernible difference in mass; representative results for N42A are shown in lane 8. These results suggest the presence of two glycosylation sites within VirB10: N32 and N97. |
View larger version (17K): [in a new window] |
FIG. 6. VirB10 contains two N-linked glycosylation sites. Immunoblot of glycine extracted proteins of C. jejuni DB179 and mutants. Lane 1, DB179; lane 2, DB179 virB10::Km; lane3, DB179 virB10::Km (pJL102); lane 4, DB179 virB10::Km (pJL102N32A); lane 5, DB179 virB10::Km (pJL102N97A); lane 6, DB179 virB10::Km (pJL102N32A,N97A); lane 7, recombinant VirB10; lane 8, DB179 virB10::Km (pJL102N42A). Anti-VirB10 antiserum was used at a 1:50,000 dilution.
|
![]() View larger version (17K): [in a new window] |
FIG. 7. Contribution of glycosylation to natural transformation. DNA (500 ng) from a streptomycin-resistant mutant of 81-176 was used to transform C. jejuni strains. Results are expressed as the total number of transformants per microgram of DNA and represent the means and standard deviations of at least three independent experiments. There was no difference in transformation ability of 81-176 and DB179 (data not shown).
|
|
|
|---|
The findings reported here demonstrate that the C. jejuni 81-176 pVir TFSS protein, VirB10, is glycosylated at two sites, N32 and N97. Thus, the two forms of VirB10 observed in wild-type DB179, both of which bound to the SBA-lectin column, represent mono- and diglycosylated forms. The minor band seen in E. coli whole cells containing pJL101 (Fig. 4, lane 3) most likely represents unprocessed VirB10. The small difference in mass (906 Da) between the VirB10 signal peptide and the N-linked glycan was not resolved in SDS-PAGE. Glycosylation of VirB10 at N97, but not N32, was essential for wild-type levels of competence. The predominant modification site appears to be N97, because the unmodified form of VirB10 (40.5 kDa) was present in glycine extracts of the VirB10 N97A mutant but not the VirB10 N32A mutant (Fig. 6). This suggests that the N97 site may be in a more favorable context for glycosylation than the N32A site, perhaps due to increased surface exposure.
The original phenotype described for pgl mutants was loss of immunoreactivity with a variety of antisera made against C. jejuni (29). This was interpreted as being due to the immunodominance of the glycan on proteins that were expressed at low levels. However, here we have reported that a glycosylated protein appeared to lose reactivity in a pgl mutant background with antiserum generated against a recombinant, unglycosylated form of the same protein. This would suggest that in the absence of glycosylation VirB10 either was not transported to the periplasm or, upon transport, was unable to interact with the other components of the TFS apparatus and was rapidly degraded. However, the VirB10 N32A, N97A mutant protein was detected in glycine extracts when overexpressed in trans from the flaA
28 promoter, which is approximately 10-fold stronger than the native virB10 promoter (P. Guerry, unpublished). This would suggest that the lack of detection of VirB10 in the pgl mutants reflects instability of the nonglycosylated protein, perhaps a result of an inability to interact with other TFSS proteins.
The six sites of potential glycosylation of the VirB10 homolog encoded by pVir are in contrast to the one or two putative glycosylation sites present in the H. pylori and Agrobacterium tumefaciens homologs, respectively. The A. tumefaciens homolog of VirB10 has been previously shown to be an inner membrane protein that spans the periplasm and interacts with other TFSS components to form a functional secretion channel (9). It is proposed for A. tumefaciens that VirB10 spans the periplasm in an oligomeric state and stabilizes interactions with other VirB proteins (4, 9, 34). In the absence of VirB10, substrates were not secreted, suggesting that the secretion channel was not formed, which underscores its role in the functionality of the system (6). From computer prediction analysis, it is believed that the C. jejuni VirB10 is structurally similar to the A. tumefaciens VirB10 and is localized and functions similarly. Mutational analyses of the genes in the ComB system of H. pylori, which share homology with the pVir TFSS, resulted in severe reductions in natural competence, suggesting that these ComB proteins form a TFSS that is involved in DNA uptake (15, 16). In C. jejuni 81-176, mutation of virB10 resulted in a modest effect on natural competence and a lesser effect on intestinal cell invasion (2, 3, 35). The pgl mutants were previously shown to have a decreased capacity to adhere and invade INT407 cells (28), and in this study we have demonstrated that pglB and pglE mutants are severely reduced in natural competence, likely due, to a limited degree, to lack of VirB10 glycosylation. The greater competence defect exhibited in the pgl mutants compared to that of the virB10 mutant suggests that additional glycoproteins are required for other steps in natural transformation. This notion is also consistent with the recent description of a putative type II secretion system involved in natural competence in C. jejuni (35). It is interesting that 8 of the 10 proteins described by Wiesner et al. (35) contain putative N-linked glycosylation sites by computer prediction. It remains to be determined if any of these proteins are glycosylated and if their function will be affected in the absence of glycosylation. Additionally, the observation that C. jejuni strains that lack pVir are competent also reinforces the notion that the pVir TFSS, while modulating competence levels, does not function as the primary DNA uptake system. Nevertheless, the modest effect of virB10 mutation on natural competence has been demonstrated by two independent groups and was able to be complemented in trans, suggesting the defect is genuine (2, 35, and this study). Speculatively, mutation of virB10 may have an indirect effect on natural competence by destabilizing other proteins that exist in the periplasm or membrane in the absence of a functional TFSS channel.
The identification of a TFSS structural protein that is glycosylated is significant on a number of levels. This is the first example, to our knowledge, of glycosylation of any TFSS protein, as well as the first function ascribed to an N-linked glycan in C. jejuni. Secondly, the plasmid-encoded pVir TFSS was presumably acquired through horizontal transfer from an unknown donor. Interestingly, the closest homolog of C. jejuni VirB10 is found in W. succinogenes, which is also the only other bacterium known to contain a putative N-linked glycosylation system homologous to the C. jejuni pgl system (1). Although the biochemical advantage of this general protein glycosylation system remains unknown, it would appear that the gene products of horizontally acquired DNA may be subject to functional restraints from the pgl glycosylation system and may need to be further modified to acclimate them to life within the C. jejuni host.
This work was supported by the Military Infectious Diseases Research Program.
Present address: Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada K1A 0R6. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»